ArticleRegenerative therapy2025
The therapeutic potential of neuroglobin-overexpressing human neural stem cells in a photothrombosis model.
Article in Regenerative therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neuroglobin (NGB) is an oxygen-binding protein with neuroprotective properties under hypoxic and ischemic conditions. It promotes cell survival, reduces oxidative stress, and activates survival-related signaling pathways. This study aimed to evaluate whether overexpression of NGB in human neural stem cells (F3.NGB) could enhance their regenerative potential and therapeutic efficacy in photothrombosis model. Methods: F3 cells were genetically engineered to overexpress NGB. In vitro proliferation and migration were assessed using CCK-8, colony forming, and scratch-based wound healing assays. In vivo, a photothrombosis-induced stroke model was used to evaluate infarct volume, transplanted cell migration and differentiation, and activation of proliferation-related signaling pathways following intravenous transplantation of F3.NGB cells. Results: NGB overexpression significantly enhanced the proliferative capacity of F3 cells, and F3.NGB cells promoted N2A cell proliferation and actively migrated in co-culture conditions. In vivo, transplantation of F3.NGB cells resulted in a significant reduction in infarct volume compared with that in the controls. Western blot analysis showed increased activation of PI3K/AKT, mTOR, and ERK signaling pathways, with decreased PTEN expression. Immunohistochemical staining confirmed that F3.NGB cells migrated to the infarcted region, differentiated into neurons and astrocytes, and showed strong Ki67 positivity, indicating active proliferation at the injury site. Conclusion: These findings demonstrate that F3.NGB cells reduce ischemic brain damage primarily by enhancing cell proliferation, and also migrate to the injury site and undergo differentiation into neurons or astrocytes. These results suggest that F3.NGB cell-based therapy may contribute to the development of advanced regenerative strategies for the treatment of ischemic stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.